#307 - It Took Months to Interpret His Genome. Claude Did It in 30 Minutes. | Dr. Euan Ashley + Mike Haney
LEVELS – A Whole New LevelShow Notes
Twenty-five years ago, sequencing the human genome seemed poised to usher in an era of personalized medicine. Dr. Euan Ashley helped turn that promise into an actual clinical experiment, leading one of the first efforts to interpret an entire human genome in the context of a real patient’s health. The challenge quickly became apparent: medicine could suddenly generate billions of data points about one person, but making sense of them was painfully slow. That history feels newly relevant. Ashley recently gave an AI system his own 15-year-old genome data and watched it reproduce most of an analysis that had originally required months of work by a team, in about 30 minutes. Meanwhile, genomics is being joined by wearables, multi-omics, and other technologies capable of tracking far more of our biology over time. In this episode of NextLevel, we use the genome revolution as a case study for what happens when our ability to measure the body advances faster than our ability to interpret and use the information. The next leap in personalized medicine may depend less on collecting another mountain of data than on building the tools, reference datasets, and healthcare systems capable of turning that information into decisions.
Free course: Improve your metabolic health Get our free email course on how glucose, nutrition, exercise, sleep, and measurement can help you build habits that support better energy and long-term health: https://levels.link/wnl
🎙️ About the Guest: Dr. Euan Ashley is Chair of the Department of Medicine at Stanford University and the Roger and Joelle Burnell Professor of Genomics and Precision Health, with appointments in medicine, genetics, and biomedical data science. He’s also the author of The Genome Odyssey: Medical Mysteries and the Incredible Quest to Solve Them. 📍What Dr. Euan Ashley & Mike Haney discussed: 03:33 What happened to the promise of personalized medicine? 06:33 The first clinical interpretation of a human genome 11:26 AI interprets in 30 minutes what once took months 21:25 Why genomics still needs better, more diverse reference data 27:41 Building a molecular map of exercise with MoTrPAC 32:01 Exercise changed nearly every organ researchers measured 39:05 Why your personal baseline can matter more than a "normal" range 42:46 How wearables opened a new era of longitudinal health data 47:48 The biggest barrier to continuous, personalized healthcare 51:39 What medical AI needs to become genuinely useful 57:05 How AI can ace medical benchmarks for the wrong reasons 58:20 The heart measurement Ashley considers a medical "holy grail"
🔗 Helpful Links: Clinical Assessment Incorporating a Personal Genome, The Lancet, 2010. Landmark integrated clinical analysis of a complete human genome. Molecular Transducers of Physical Activity Consortium (MoTrPAC), NIH Common Fund. Large-scale project mapping how exercise changes tissues and organs. MoTrPAC: Human Studies Design and Protocol, Journal of Applied Physiology, 2024. Human study of molecular responses to endurance and resistance training. The Mitochondrial Multi-Omic Response to Exercise Training Across Rat Tissues, Cell Metabolism, 2024. MoTrPAC study on molecular changes across organs after exercise. Harmonizing Standards and Resources for the Medical Genome, Nature, 2026. Ashley et al. on genomic reference standards and clinical-grade sequencing.
Watch the conversation: https://youtu.be/bD2YVGdwviE Find us on YouTube: https://youtube.com/levelshealth?sub_confirmation=1
👋 Who we are: Levels helps you understand your metabolic health with personalized data, expert guidance, and tools that connect your daily choices to measurable changes in your body. Our goal is to help you make better decisions about food, exercise, sleep, and long-term health.
Look for new shows every month on A Whole New Level, where we have in-depth conversations with thought leaders about metabolic health.
More from LEVELS – A Whole New Level
Heart disease is the leading cause of death, but it’s also one of the most preventable. Decades of research have established a strong causal role for LDL and other ApoB-containing particles in atherosclerosis, and we now have multiple proven ways to lower them. The harder question is how to turn that evidence into a decision for an individual person. Mike Haney talks with Johns Hopkins cardiologist Dr. Seth Martin, a co-author of the new 2026 dyslipidemia guidelines, about what the latest evidence says we should actually measure and act on. The throughline is pragmatic: lower exposure to atherogenic particles earlier and for longer, use additional tests when they can change a decision, and distinguish interesting new measurements from ones that have actually been shown to improve outcomes.
Most of NextLevel starts with a measurement problem: we can see more biology than ever, but we still have to figure out what to do with it. Bioelectronic medicine flips that sequence. We already know how to send electrical signals into the nervous system to change biology, including an FDA-approved vagus nerve treatment for rheumatoid arthritis, even though we still can’t map or read most of the individual nerve fibers carrying those signals.
Most health decisions happen before the science is settled. A study points one way, another points somewhere else, experts disagree about what matters, and even strong population-level evidence may not tell you what will happen to you.
Most medical imaging happens after a symptom, injury, or abnormal test gives a clinician a reason to look. But what changes if imaging becomes a more routine measurement, creating a record of the body before something goes wrong? In this episode of Next Level, Mike Haney talks with Dr. Daniel Durand, chief medical officer at Prenuvo, about whole-body MRI as a test case for a broader shift from episodic medicine toward longitudinal health data. Whole-body MRI is controversial, and Durand is clearly an advocate. The conversation takes the skepticism seriously, then asks a larger question: as measurement gets cheaper, more frequent, and increasingly visible to patients themselves, how should medicine decide what is worth knowing?
Alcohol has spent the last 40 years bouncing between two health narratives: a little is good for your heart, or any amount is dangerous. The science doesn’t really support either slogan. Dr. Tim Naimi has spent decades studying the health effects of alcohol and, just as importantly, why the research is so difficult to interpret. His read of the evidence is less dramatic but more useful: there’s no good reason to start drinking for your health, very low intake may carry little measurable added risk, and risk rises as consumption does. Understanding why earlier studies made moderate drinking look protective helps explain a lot of the whiplashing headlines.